Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.45% is 67% below its 5-year average of 31.50%, near the low end of its 5-year range (3.24%–87.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 74.40% below its 12-month average of 40.80%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.45%.
DEBT TO ASSETS RATIO
10.45%
DEBT TO ASSETS RATIO AVG TTM
40.80%
DEBT TO ASSETS RATIO AVG 3Y
8.25%
DEBT TO ASSETS RATIO AVG 5Y
31.50%
DEBT TO ASSETS RATIO AVG 10Y
21.78%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-74.40%
CURRENT VS 3Y AVG
+26.54%
CURRENT VS 5Y AVG
-66.83%
CURRENT VS 10Y AVG
-52.04%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 732 covered companies
CURRENT VS SECTOR MEDIAN
+10345.79%
vs the sector median at left
Cibus, Inc.
Market Cap
$122.89M
Debt to Assets Ratio
10.45%
TTM Avg
40.80%
3Y Avg
8.25%
5Y Avg
31.50%
Market Cap
$122.93M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$121.90M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$124.91M
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.68M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.02M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$117.29M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.59M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cibus, Inc. (CBUS) | $122.89M | 10.45% | 40.80% | 8.25% | 31.50% |
| enGene Holdings Inc. (ENGN)vs › | $122.93M | 0.12% | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.90M | 0.01% | N/A | N/A | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $124.91M | 0.04% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.68M | 0.00% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 0.19% | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $128.40M | 0.02% | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.29M | 0.00% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | 0.09% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.49M | 0.21% | N/A | N/A | N/A |
Debt/Assets
10.4%
Debt/Equity
2.21
Current Ratio
1.62
Interest Coverage
-1.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 10.45% |
| 2026-03-31 | 85.18% |
| 2025-12-31 | 87.84% |
| 2025-09-30 | 10.28% |
| 2025-06-30 | 10.23% |
| 2025-03-31 | 10.64% |
| 2024-12-31 | 10.37% |
| 2024-09-30 | 9.99% |
| 2024-06-30 | 13.48% |
| 2024-03-31 | 4.29% |
| 2023-12-31 | 4.52% |
| 2023-09-30 | 3.32% |
| 2023-06-30 | 3.24% |
| 2023-03-31 | 72.67% |
| 2022-12-31 | 62.04% |
| 2022-09-30 | 51.19% |
| 2022-06-30 | 43.52% |
| 2022-03-31 | 36.83% |
| 2021-12-31 | 48.06% |
| 2021-09-30 | 45.47% |
| 2021-06-30 | 37.81% |
| 2021-03-31 | 37.52% |
| 2020-12-31 | 31.20% |
| 2020-09-30 | 31.85% |
| 2020-06-30 | 29.41% |
| 2020-03-31 | 24.28% |
| 2019-12-31 | 21.11% |
| 2019-09-30 | 19.38% |
| 2019-06-30 | 17.93% |
| 2019-03-31 | 16.65% |
| 2018-12-31 | 15.56% |
| 2018-09-30 | 13.99% |
| 2018-06-30 | 13.54% |
| 2018-03-31 | 20.53% |
| 2017-12-31 | 14.06% |
| 2017-09-30 | 10.50% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
